People who use opioids and stimulants concurrently have more than twice the risk of fatal overdose compared to individuals who use opioids only, according to a 2022 study. Despite the increased risk of overdose bolstered by the ever-changing and adulterated drug supply, research indicates a lack of training and programming that specifically addresses treating and managing co-occurring opioid and stimulant use disorders.
While medication for opioid use disorder (MOUD) is the gold standard of care for treating opioid use disorder, there are no FDA-approved medications to treat stimulant use disorder, though behavioral therapies like contingency management have been well-studied. These challenges highlight the need to identify promising treatment strategies to ensure individuals with co-occurring opioid and stimulant use disorders are effectively engaged in care to prevent overdose.
Join this webinar to discuss evidence-based and promising strategies to treat co-occurring opioid and stimulant use disorders and review psychiatric co-morbidities associated with them. This session will equip mental health and substance use treatment providers and organizations, including Community Behavioral Health Clinics (CCBHCs), with the tools necessary to effectively engage and provide quality, team-based care and services to clients with co-occurring opioid and stimulant use disorders to improve health outcomes, reduce overdose risk and support long-term recovery.
The webinar will:
- Describe the broad context of co-occurring opioid and stimulant use and overdose risk in the U.S.
- Review evidence-based strategies to treat opioid use disorders and promising practices for stimulant use.
- Identify evidence-based and promising strategies to treat co-occurring opioid and stimulant use disorders.
- Review psychiatric co-morbidities associated with opioid and stimulant use disorders.